March 8, 2013Cumberland Pharmaceuticals Inc • March 12th, 2013 • Pharmaceutical preparations
Re: Employment of Martin E. Cearnal as Senior Vice President and Chief Commercial Officer by Cumberland Pharmaceuticals Inc.
AMENDED AND RESTATED 2007 LONG-TERM INCENTIVE COMPENSATION PLAN INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • March 12th, 2013 • Cumberland Pharmaceuticals Inc • Pharmaceutical preparations • Tennessee
WAIVER AND SECOND AMENDMENT TO FIFTH AMENDED AND RESTATED LOAN AGREEMENTLoan Agreement • March 12th, 2013 • Cumberland Pharmaceuticals Inc • Pharmaceutical preparations • Tennessee
THIS WAIVER AND SECOND AMENDMENT TO FIFTH AMENDED AND RESTATED LOAN AGREEMENT (this "Amendment"), dated as of March 7, 2013, is made and entered into on the terms and conditions hereinafter set forth, by and between CUMBERLAND PHARMACEUTICALS INC., a Tennessee corporation (the "Borrower"), and BANK OF AMERICA, N.A., a national banking association (the "Bank").
LICENSE AND SUPPLY AGREEMENTLicense and Supply Agreement • March 12th, 2013 • Cumberland Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This License and Supply Agreement (“Agreement”) is entered into this 9th day of November, 2012 (“Effective Date”) by and between Cumberland Pharmaceuticals Inc., a Tennessee corporation having its principal place of business at 2525 West End Ave., Suite 950, Nashville, Tennessee 37023 (“Cumberland”), Paddock Laboratories, LLC, a Delaware limited liability company having its principal place of business at 3940 Quebec Avenue N, Minneapolis, Minnesota 55427 (“Paddock”) and Perrigo Company, a Michigan corporation having its principal place of business at 515 Eastern Avenue, Allergan, Michigan 49010 (“Perrigo”). Each of Cumberland, Paddock and Perrigo may be referred to herein individually as a “Party” and collectively as the “Parties”, and each of Perrigo and Paddock may be referred to herein as a “Defendant” and together as the “Defendants”.
FIRST AMENDMENT TO FIFTH AMENDED AND RESTATED LOAN AGREEMENTLoan Agreement • March 12th, 2013 • Cumberland Pharmaceuticals Inc • Pharmaceutical preparations • Tennessee
THIS FIRST AMENDMENT TO FIFTH AMENDED AND RESTATED LOAN AGREEMENT (this "Amendment"), dated as of March 29, 2012, is made and entered into on the terms and conditions hereinafter set forth, by and between CUMBERLAND PHARMACEUTICALS, INC., a Tennessee corporation (the "Borrower"), and BANK OF AMERICA, N.A., a national banking association (the "Bank").
AMENDED AND RESTATED 2007 DIRECTORS' INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENTNon-Statutory Stock Option Agreement • March 12th, 2013 • Cumberland Pharmaceuticals Inc • Pharmaceutical preparations • Tennessee
Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment which has been filed separately with the SEC. SETTLEMENT AGREEMENTSettlement Agreement • March 12th, 2013 • Cumberland Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Settlement Agreement (“Agreement”) is entered into this 9th day of November, 2012 (“Effective Date”) by and between Cumberland Pharmaceuticals Inc., a Tennessee corporation having its principal place of business at 2525 West End Ave., Suite 950, Nashville, Tennessee 37023 (“Cumberland”), Paddock Laboratories, LLC, a Delaware limited liability company having its principal place of business at 3940 Quebec Avenue N, Minneapolis, Minnesota 55427 (“Paddock”) and Perrigo Company, a Michigan corporation having its principal place of business at 515 Eastern Avenue, Allergan, Michigan 49010 (“Perrigo”). Each of Cumberland, Paddock and Perrigo may be referred to herein individually as a “Party” and collectively as the “Parties”, and each of Perrigo and Paddock may be referred to herein as a “Defendant” and together as the “Defendants”.
AMENDED AND RESTATED 2007 LONG-TERM INCENTIVE COMPENSATION PLAN NON-STATUTORY STOCK OPTION AGREEMENTNon-Statutory Stock Option Agreement • March 12th, 2013 • Cumberland Pharmaceuticals Inc • Pharmaceutical preparations • Tennessee
